
Wegovy GLP-1 pill now available; early vaccine delays predict missed MMR shots; pre-op stress tied to tougher recovery in older patients – Morning Medical Update
Key Takeaways
- Novo Nordisk's oral Wegovy offers a non-injection option for chronic weight management, with similar efficacy to injections and a starting price of $149 per month.
- Delays in early childhood immunizations significantly increase the risk of missing the MMR vaccine, with timely vaccination rates declining from 2021 to 2024.
The top news stories in medicine today.
Novo Nordisk’s pill version of Wegovy is now available at U.S. pharmacies, marking the first FDA-approved oral GLP-1 for chronic weight management. Approved in late December, the drug offers an alternative to weekly injections for patients with obesity or overweight and is also cleared to reduce the risk of heart attack and stroke in high-risk patients. Clinical trial data showed weight loss comparable to the injectable form, with patients losing about 13.6% of body weight over 64 weeks on the highest dose. The pill must be taken on an empty stomach and carries similar gastrointestinal side effects as injections.
Children who fall behind on routine immunizations in the first months of life are far more likely to miss their first measles, mumps and rubella (MMR) vaccine altogether, according to a new study published in
Even relatively mild worries before surgery may set older adults up for a harder recovery, according to a new Duke University study published in
Newsletter
Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.








